Table 2 IVF cycles characteristics of patients undergoing endometrial injury in proliferative phase, luteal phase and control groups
Variable | Group A | Group B | Group C | Group D | P value |
|---|---|---|---|---|---|
(n = 38) | (n = 32) | (n = 36) | (n = 36) | ||
Basal FSH(IU/L) | 6.85 ± 1.78 | 6.65 ± 1.76 | 7.73 ± 1.70 | 7.17 ± 1.82 | 0.091 |
Basal LH(IU/L) | 4.29 ± 1.82 | 4.56 ± 1.83 | 4.34 ± 2.07 | 5.05 ± 2.82 | 0.746 |
Basal E2(pg/mL) | 42.96 ± 27.59 | 36.60 ± 15.78 | 41.09 ± 23.79 | 47.78 ± 39.07 | 0.651 |
Basal AFC | 13 ± 4 | 13 ± 5 | 12 ± 6 | 13 ± 6 | 0.240 |
Protocol | 0.147 | ||||
Long agonist | 26(68.4%) | 21 (65.6%) | 25(69.4%) | 20 (55.6%) | |
Short agonist | 1(2.6%) | 4 (12.5%) | 4(11.1%) | 6 (16.7%) | |
Antagonist | 11(29.0%) | 7 (21.9%) | 7(19.5%) | 10 (27.7%) | |
Insemination | 0.706 | ||||
IVF | 23(60.5%) | 21(65.6%) | 22(61.1%) | 26(72.2%) | |
ICSI | 15(39.5%) | 11(34.4%) | 14(38.9%) | 10(27.8%) | |
Total gonadotrophin used (IU) | 1971.7 ± 797.8 | 2217.2 ± 791.2 | 2467.4 ± 1129.9 | 2406.9 ± 1033.3 | 0.090 |
Duration of hormonal stimulation(d) | 9.5 ± 1.2 | 9.9 ± 1.2 | 10.1 ± 1.5 | 10.1 ± 1.2 | 0.055 |
Endometrial thickness on HCG day(cm) | 1.03 ± 0.18 | 0.97 ± 0.17 | 1.01 ± 0.17 | 1.03 ± 0.19 | 0.446 |
Peak E2 on HCG day (pg/mL) | 4071.4 ± 2582.5 | 4154.5 ± 2283.6 | 3291.3 ± 2135.0 | 2960.5 ± 1985.9 | 0.060 |
Number of transferred embryos | 2.0 ± 0.6 | 2.0 ± 0.6 | 2.0 ± 0.5 | 2.0 ± 0.5 | 0.527 |